无论是胸腺切除术（TM）还是胸腺瘤切除术（TMM）对于早期胸腺瘤非重症肌无力患者来说更好，我们进行了一项Meta分析，比较了采用胸腺切除术与胸腺瘤切除术治疗早期胸腺瘤的非重症肌无力患者的临床疗效和预后。我们系统检索了PubMed、Embase、Cochrane Library和CNKI数据库，收集了2022年3月之前发表的关于非重症肌无力患者早期胸腺瘤手术治疗（TM和TMM）的相关研究。采用Newcastle-Ottawa评分法评估研究的质量，并使用RevMan 5.30分析数据。随着异质性的不同，采用固定效应模型或随机效应模型进行Meta分析。进行亚组分析，比较短期围手术期和长期肿瘤效果。电子数据库中共鉴定了15项符合条件的研究，包括3023名患者。我们的分析表明，TMM患者可能受益于手术时间短（p=0.006）、失血量少（p<0.001）、术后引流减少（p=0.03）和住院时间短（p=0.009）。两种手术治疗组总体生存率（p=0.47）和无病生存率（p=0.66）没有显着差异。同样地，TM和TMM在辅助治疗（p=0.29）、切除完整性（p=0.38）和术后胸腺瘤复发（p=0.99）方面相似。我们的研究揭示出，TMM可能是治疗早期胸腺瘤非重症肌无力患者更合适的选择。 版权所有©2023亚洲外科协会和台湾机器人手术协会。由Elsevier B.V.出版。保留所有权利。

Whether thymectomy (TM) or thymomectomy (TMM) is better for non-myasthenic patients with early-stage thymoma. We conducted a meta-analysis to compare the clinical outcomes and prognoses of non-myasthenic patients with early-stage thymoma treated using thymectomy versus thymomectomy. PubMed, Embase, Cochrane Library and CNKI databases were systematically searched for relevant studies on the surgical treatment (TM and TMM) of non-myasthenic patients with early-stage thymoma published before March 2022. The Newcastle-Ottawa scale was used to evaluate the quality of the studies, and the data were analyzed using RevMan version 5.30. Fixed or random effect models were used for the meta-analysis depending on heterogeneity. Subgroup analyses were performed to compare short-term perioperative and long-term tumor outcomes. A total of 15 eligible studies, including 3023 patients, were identified in the electronic databases. Our analysis indicated that TMM patients might benefit from a shorter duration of surgery (p = 0.006), lower blood loss volume (p < 0.001), less postoperative drainage (p = 0.03), and a shorter hospital stay (p = 0.009). There were no significant differences in the overall survival rate (p = 0.47) or disease-free survival rate (p = 0.66) between the two surgery treatment groups. Likewise, TM and TMM were similar in the administration of adjuvant therapy (p = 0.29), resection completeness (p = 0.38), and postoperative thymoma recurrence (p = 0.99). Our study revealed that TMM might be a more appropriate option in treating non-myasthenic patients with early-stage thymoma.Copyright © 2023 Asian Surgical Association and Taiwan Robotic Surgery Association. Published by Elsevier B.V. All rights reserved.